These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28766370)

  • 1. Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands.
    Jacobs MS; van Leent MWJ; Tieleman RG; Jansman FGA; Cao Q; Postma MJ; van Hulst M
    J Med Econ; 2017 Dec; 20(12):1231-1236. PubMed ID: 28766370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
    Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG
    Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
    Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
    J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.
    Reynolds SL; Ghate SR; Sheer R; Gandhi PK; Moretz C; Wang C; Sander S; Costantino ME; Annavarapu S; Andrews G
    Health Qual Life Outcomes; 2017 Jun; 15(1):128. PubMed ID: 28637460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
    Lauffenburger JC; Farley JF; Gehi AK; Rhoney DH; Brookhart MA; Fang G
    J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25862791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation.
    Francis K; Yu C; Alvrtsyan H; Sander S; Ghosh S; Rao Y; Sanchez H; Matchar D
    Curr Med Res Opin; 2015 Dec; 31(12):2189-95. PubMed ID: 26359333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.
    Lip GYH; Lane DA; Buller H; Apostolakis S
    Chest; 2013 Dec; 144(6):1839-1847. PubMed ID: 24009027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Retrospective Population Study.
    Chi NF; Wang Y; Chien LN; Chien SC; Ko Y
    Med Care; 2018 May; 56(5):410-415. PubMed ID: 29578954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France.
    Cotté FE; Chaize G; Kachaner I; Gaudin AF; Vainchtock A; Durand-Zaleski I
    J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e73-83. PubMed ID: 24119623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study.
    Roldán V; Cancio S; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Am J Med; 2015 Nov; 128(11):1237-43. PubMed ID: 26087049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose dabigatran versus uninterrupted acenocoumarol for peri-procedural anticoagulation in atrial fibrillation catheter ablation.
    Efremidis M; Vlachos K; Letsas KP; Giannopoulos G; Lioni L; Georgopoulos S; Vadiaka M; Deftereos S; Sideris A
    J Electrocardiol; 2015; 48(5):840-4. PubMed ID: 26152604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I; Smith KJ; Zhang Y
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
    O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States.
    Bancroft T; Lim J; Wang C; Sander SD; Swindle JP
    Clin Ther; 2016 Mar; 38(3):545-56.e1-6. PubMed ID: 26856927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score].
    Giner-Soriano M; Casajuana M; Roso-Llorach A; Vedia C; Morros R
    Aten Primaria; 2020 Mar; 52(3):176-184. PubMed ID: 31551166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.
    Lauffenburger JC; Rhoney DH; Farley JF; Gehi AK; Fang G
    Pharmacotherapy; 2015 Jun; 35(6):560-8. PubMed ID: 26044889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.